Skip to search formSkip to main contentSkip to account menu

ACE-041

Known as: ALK1-Fc Fusion Protein ACE-041, Activin Receptor-like Kinase 1 Inhibitor ACE-041 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

dalantercept

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Abstract LB-313: ALK1-Fc inhibits tumor growth in a VEGF pathway resistance model of renal cell carcinoma
Treatment of metastatic RCC with agents that block signaling through VEGFR2 induces disease stabilization or regression in a… 
2012
2012
BMP9 as a potential biomarker for dalantercept efficacy against ALK1-mediated angiogensis in head and neck cancer.
30 Background: Activin receptor-like kinase 1 (ALK1) is a type 1 receptor in the TGF-β superfamily. The ALK1 pathway plays a role… 
2011
2011
Phase I study of ACE-041, a novel inhibitor of ALK1-mediated angiogenesis, in patients with advanced solid tumors.
3070 Background: Activin receptor-like kinase-1 (ALK1) is a type I receptor in the TGFß superfamily expressed on endothelial… 
2011
2011
Abstract 3276: A Phase 1 dose escalating study with ACE-041, a novel inhibitor of ALK1 mediated angiogenesis, in patients with advanced solid tumors
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Background: Activin receptor-like kinase-1 (ALK1) is a… 
2010
2010
465 DISCUSSION A Phase 1 dose escalating study of ACE-041, a novel inhibitor of ALK-1 mediated angiogenesis, in patients with advanced solid tumors
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)